key: cord-0701881-nc2p1usi authors: Griswold, Matthew K.; Chai, Peter R.; Brent, Jeffrey; Weiss, Stephanie; Askman, Noah; Wax, Paul M.; Farrugia, Lynn A. title: Hydroxychloroquine and Chloroquine Toxicity as Reported by Medical Toxicologists to the Toxicology Investigators Consortium (ToxIC) Registry date: 2022-04-28 journal: J Med Toxicol DOI: 10.1007/s13181-022-00893-4 sha: 998e4f119562af33c524139c2cb551f3da695249 doc_id: 701881 cord_uid: nc2p1usi nan Chloroquine and hydroxychloroquine, 4-aminoquinoline drugs, have long-standing use as antimalarials and in inflammatory conditions. Early investigations in pharmacotherapy to treat Coronavirus Disease 2019 (COVID-19) infections focused on hydroxychloroquine as a promising candidate [1] [2] [3] . The Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) on March 28, 2020, for the treatment of COVID-19 with chloroquine and hydroxychloroquine in the context of clinical trials [4] . Later investigations demonstrated increased morbidity and mortality, largely owing to cardiotoxicity associated with hydroxychloroquine [5] . The FDA retracted its EUA on June 15, 2020, warning not to use these agents to treat COVID-19 [6] . According to the FDA Adverse Effects Reporting System, in the first 7 months of 2020 there were 20 reports of death where hydroxychloroquine was listed as the primary agent in individuals using it as an unapproved COVID-19 treatment [7] . In order to better define the toxic profile of individuals who may experience poisoning by hydroxychloroquine and the related drug chloroquine, we utilized the Toxicology Investigators Consortium (ToxIC) Case Registry to describe the largest case series to date that includes clinical presentations and treatments recorded prior to the COVID-19 pandemic. We describe available information from the Registry on critical illness, including information on hemodynamic instability, central nervous system (CNS) depression, seizures, and death as well as intention of exposure. The ToxIC Registry was established by the American College of Medical Toxicology in 2010 [8] . All cases entered into the Registry have been evaluated at the bedside by a board-eligible or board-certified medical toxicologist. There are currently > 50 participating facilities across the USA with additional sites in Canada, Israel, and Thailand [8] . The Registry has been reviewed by the Western Institutional Review Board (IRB) and operates in pursuant to the approval of the participating site IRBs. Data were queried from the initiation of the Registry in January 2010 through 31 December 2019. Cases were included if they listed chloroquine or hydroxychloroquine as the agent of exposure in any primary agent field. Cases were excluded if they did not list chloroquine or hydroxychloroquine as a primary agent. Demographic variables are presented descriptively, including intention of exposure if known. Continuous clinical variables including hemodynamics were presented as the mean (range). We reported frequency of therapies and antidotes reported in the registry. In cases where demographic information such as race was not recorded this was reported with the results. Fifty-two cases met inclusion criteria: 48 involving hydroxychloroquine and 4 involving chloroquine. Available case demographics including gender, age range, and ethnicity are listed in Table 1 . The most common clinical symptoms were hypotension with a systolic blood pressure < 80 mmHg (32.7%), QTc prolongation > 500 ms (msec) (26.9%) with a median reported of 510.6 ms (range 309-789 ms), and CNS depression (38.5%). Further clinical features and a complete list of treatments performed are listed in Table 2 . Thirty-seven of the 52 cases (71.2%) involved intentional ingestions and 22 (59.5%) of them were attempts at selfharm. The other cases reflected therapeutic intent. There was one death reported (1.9%), with life support being withdrawn in that case. About half of patients with an intentional ingestion (48.6%) required intensive care admission. Fifteen cases reported hypotension (40.5%) and 13 (35.1%) reported QTc prolongation. Twenty (54.1%) experienced coma or central nervous system depression of which 10 (19.2%) required intubation or ventilatory management. There were 12 cases (23.1%) of unintentional exposures, none of which required treatment interventions. Nine of these (75.0%) were age 6 or less. Only a single case of an 82-year-old man presenting for evaluation of an unintentional exposure reported delirium or toxic psychosis. Acetaminophen was reported in 5 cases. Additional isolated coingestants included a variety of agents. When considered as agent classes, the most commonly reported were cardiovascular agents with 11 cases and analgesics with 10 cases. Antidepressants and sedative/hypnotic agents each were reported in 7 cases. Overdose events related to chloroquine/hydroxychloroquine have been reported related to COVID-19 [7, 9, 10] . Hydroxychloroquine remains an important and relatively commonly prescribed pharmaceutical used in the treatment of a variety of disorders. Our data demonstrate the clinical severity of hydroxychloroquine overdose cases managed by medical toxicologists and describe therapies that were used to manage these poisonings. Poisoning from hydroxychloroquine most commonly manifested in this study with clinically significant hypotension, prolonged QTc, abnormal heart rate, and central nervous system depression. In this data set, there appeared to be a divergence in the severity of presentation between patients who presented with unintentional exposures as opposed to intentional ingestions. Specific laboratory values including potassium were not available for analysis. The clinical features that prompted intervention were more commonly seen in individuals who intentionally overdosed on hydroxychloroquine, most likely because they ingested a higher dose than those with unintentional exposures. Clinicians who evaluate individuals with an intentional overdose of hydroxychloroquine or chloroquine should closely monitor patients for signs of cardiotoxicity and neurotoxicity. Traditional therapies recommended to manage hydroxychloroquine overdose include high dose diazepam, epinephrine and endotracheal intubation [11, 12] . In contrast to previously published recommendations on early intubation, our study found that few individuals ultimately required intubation, and most were successfully managed with benzodiazepines and other supportive measures. This may be reflective of the predominance of hydroxychloroquine in our study as opposed to chloroquine in previous studies [12] . However, the majority of individuals included in this study comprised intentional overdoses with suicidal intent. These larger ingestions were more likely to be symptomatic than the general population of all exposed patients or those taking therapeutic doses. QTC corrected QT, CNS central nervous system **More than one clinical sign and symptom could be present in a single case, so the total sum is greater than 100% *** Some Registry fields are created as a binary field definition. For example, tachycardia is defined as a heart rate > 140 beats per minute and is entered as a yes/no data point. Where relevant, these definitions are indicated While epinephrine is the recommended vasopressor of choice, less than half of individuals who required vasopressor support received epinephrine. In this cohort the most common pharmacologic intervention among hydroxychloroquine poisoned individuals was benzodiazepines; however, which benzodiazepine used was not specified, so it is unknown whether diazepam was the preferred agent in this group. Limitations to this study include those inherent to a registry collection and have been previously described, including limited information on amount of xenobiotic ingested and lack of laboratory confirmation [13, 14] . Specific case details and laboratory values of interest may not be available. This registry relies on data entry from medical toxicologists who perform bedside evaluations; cases likely skew towards more symptomatic exposures who received a toxicology consultation, and therefore may not be generalizable to all ingestions. Although hydroxychloroquine and chloroquine poisoning cases reported to the ToxIC Registry over the past ten years are rare, this report demonstrates the severity of toxicity due to these agents in cases managed by medical toxicologists and summarizes the therapies that may be used to manage such poisonings. This propensity toward severe effects warrants thorough evaluation and monitoring of all patients with hydroxychloroquine or chloroquine toxicity. We plan to continue to monitor these cases through the ToxIC Registry and report on trends in use of chloroquine and hydroxychloroquine as they continue. Funding PRC funded by NIH K23DA044874, R44DA051106, Hans and Mavis Psychosocial Foundation, e-ink corporation. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro Chloroquine is a potent inhibitor of SARS coronavirus infection and spread Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Fact Sheet for Health Care Providers Emergency Use Authorization (EUA) of Hydroxychloroquine Sulfate Supplied from the Strategic National Stockpile for Treatment of COVID-19 in Certain Hospitalized Patients. Food and Drug Administration Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in 19-update-fda-revok es-emerg ency-use-autho rizat ion-chlor oquineand US Food and Drug Administration. FDA Adverse Events Reporting System (FAERS) Public Dashboard The Toxicology Investigators Consortium (ToxIC) Registry Man Fatally Poisons Himself While Self-Medicating for Coronavirus, Doctor Says Florida teen COVID-19 victim received unproven treatment at home before dying at hospital, report says COVID-19: Therapeutics and Their Toxicities Treatment of Severe Chloroquine Poisoning The Toxicology Investigators Consortium Case Registry-the 2018 Annual Report The Toxicology Investigators Consortium Case Registry-The 2012 Experience